NEUFELD, Austria, Feb. 25, 2025 /PRNewswire/ -- Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen, The Netherlands). The multicentric prospective...
Hence then, the article about sanochemia spl investigational iron based mri contrast agent meets primary endpoints in pivotal phase iii study was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study )
Also on site :
- What are Brownfields?
- 1971 Rock Ballad, Inspired by a Mysterious Vision, Was Rejected by Lead Singer Before Becoming a Timeless Classic
- Ukraine-Russia war latest: Putin and Zelensky vow to escalate fighting after deadliest strike on Kyiv this year